Michael Nieder
Overview
Explore the profile of Michael Nieder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1011
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kassim A, Walters M, Eapen M, Smith M, Logan B, Solh M, et al.
NEJM Evid
. 2025 Feb;
4(3):EVIDoa2400192.
PMID: 39998298
Background: Related human leukocyte antigen (HLA)-haploidentical bone marrow transplantation (BMT) with posttransplant cyclophosphamide may be curative for sickle cell disease. However, graft failure, severe graft-versus-host disease (GVHD), infections, and mortality...
2.
Adoncecchi G, Kumar A, Mogili K, Faramand R, Liu H, Khimani F, et al.
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39858092
Background: Previous studies have shown that allogeneic peripheral blood stem cell transplantation (PBSCT) from an HLA haploidentical (haplo) donor followed by graft-versus-host disease (GVHD) prophylaxis with post-transplant cyclophosphamide (PTCy) results...
3.
Handley G, Yepes A, Eliassen E, Dominguez G, Pasikhova Y, Klinkova O, et al.
Open Forum Infect Dis
. 2024 Oct;
11(10):ofae564.
PMID: 39411216
Background: Human herpesvirus 6B (HHV-6B) frequently reactivates following allogeneic stem cell transplant (alloHCT). Consensus guidelines note that haploidentical alloHCT may represent a high-risk population for which there is little evidence;...
4.
Albanyan O, Elmariah H, Kalos D, Kim J, Faramand R, Sallman D, et al.
Transplant Cell Ther
. 2024 Aug;
30(11):1090.e1-1090.e10.
PMID: 39147136
Fludarabine (Flu) and melphalan (Mel) reduced-intensity conditioning is frequently used for allogenic hematopoietic cell transplant (allo-HCT) in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). However, there is...
5.
Elmariah H, Otoukesh S, Kumar A, Ali H, Arslan S, Dimaggio E, et al.
Transplant Cell Ther
. 2024 Aug;
30(10):1019.e1-1019.e9.
PMID: 39102983
Mycophenolate mofetil (MMF) is commonly included in post-transplant cyclophosphamide (PTCy) based graft-versus-host disease (GVHD) prophylaxis after haploidentical (haplo) hematopoietic cell transplant (HCT). In the non-PTCy setting, higher MMF dose/kg has...
6.
Caprice T, Fan W, Kim J, Faramand R, Mishra A, Perez L, et al.
Am J Hematol
. 2024 Mar;
99(6):1196-1200.
PMID: 38546371
No abstract available.
7.
Elmariah H, Otoukesh S, Kumar A, Ali H, Arslan S, Shouse G, et al.
Transplant Cell Ther
. 2023 Nov;
30(2):229.e1-229.e11.
PMID: 37952648
Graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF) for allogeneic haploidentical donor (haplo) hematopoietic cell transplantation (HCT) results in comparable outcomes to matched unrelated...
8.
Keit E, Liveringhouse C, Figura N, Weygand J, Sandoval M, Garcia G, et al.
Technol Cancer Res Treat
. 2023 Jun;
22:15330338231180779.
PMID: 37287260
High-dose total body irradiation (TBI) is often part of myeloablative conditioning in acute leukemia. Modern volumetric modulated arc therapy (VMAT)-based plans employ arcs to the inferior-most portion of the body...
9.
Crowder S, Sauls R, Redwine L, Nieder M, Albanyan O, Yasin H, et al.
Cancers (Basel)
. 2022 Jun;
14(11).
PMID: 35681740
Previous adolescent and young adult (AYA) research suggests patients undergoing hematopoietic stem cell transplantation (HSCT) experience severe physiological stress. The goal of this study was to identify unmet needs, interests,...
10.
Mirza A, Tandon A, Jenneman D, Cao S, Brimer T, Kumar A, et al.
Transplant Cell Ther
. 2022 Jan;
28(4):185.e1-185.e7.
PMID: 35017119
Although tacrolimus and sirolimus (TAC/SIR) is an accepted graft-versus-host disease (GVHD) prophylaxis regimen following allogeneic hematopoietic cell transplantation (HCT), toxicity from this regimen can lead to premature discontinuation of immunosuppression....